Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SOD1 | P00441 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569052 | 1.00 | MAOB (0.46) | MAOBKDM4EPOLBGAAALDH1A1 | |
| SCHEMBL19291625 | 0.81 | CYP3A4 (0.49) | MAOBPOLBALDH1A1MAPT | |
| SCHEMBL4421914 | 0.81 | AGXT (0.39) | — | |
| SCHEMBL25820166 | 0.81 | KDM4E (0.48) | KDM4EGAAKMT2AMEN1RAB9A | |
| SCHEMBL2207575 | 0.79 | TAAR1 (0.43) | — | |
| SCHEMBL2208263 | 0.79 | TAAR1 (0.43) | — | |
| SCHEMBL4568909 | 0.79 | KMT2A (0.47) | KDM4EALDH1A1KMT2AHTT | |
| SCHEMBL2202557 | 0.79 | TAAR1 (0.43) | — | |
| SCHEMBL4568776 | 0.79 | KMT2A (0.47) | KDM4EALDH1A1KMT2AHTT | |
| SCHEMBL29818722 | 0.79 | TAAR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2018-06-28 | — | — | US | disclosed |
| EP-3210966-A1 | ALKOXYPHENYLPROPYLAMINES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Acucela, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9737496-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737496-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2017-02-23 | — | — | US | disclosed |
| US-9458088-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | MAOB 318/4885KDM4E 2349/4885POLB 1979/4885 |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | MAOB 318/4885KDM4E 2349/4885POLB 1979/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | MAOB 332/4885KDM4E 2227/4885POLB 2057/4885 |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | MAOB 318/4885KDM4E 2349/4885POLB 1979/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | MAOB 318/4885KDM4E 2349/4885POLB 1979/4885 |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | MAOB 318/4885KDM4E 2349/4885POLB 1979/4885 |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | MAOB 318/4885KDM4E 2349/4885POLB 1979/4885 |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | MAOB 318/4885KDM4E 2349/4885POLB 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.